On Friday, Nasdaq Inc's (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on December 23.

Also Read: Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination

The company has witnessed a decline in its only approved product, Spikevax, the COVID-19 vaccine.

However, Moderna witnessed some relief on higher third-quarter sales attributed to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine.

Moderna unveiled key updates at its annual R&D Day in September, spotlighting its mRNA-based pipeline and revised financial plans.

Faced with commercial challenges, Moderna is adopting a more selective approach to R&D investments. The company anticipates maintaining substantial R&D investment, especially in oncology and rare diseases, while pacing other expenditures.

GSK Plc (NYSE:GSK) also filed a lawsuit alleging that Moderna's mRNA vaccines infringe on patents it developed.

Price Action: MRNA stock is down 1.04% at $41.40 at the last check on Monday.

Read Next:

• Taiwan Semiconductor CEO Highlights AI-Powered Drones, Next-Gen Robots As Growth Drivers

Photo via Wikimedia Commons